This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Elevance Health (ELV) to Expand in 91 New Counties in 2024
by Zacks Equity Research
Elevance Health (ELV) is set to enhance its product suite and expand to 91 counties in 2024, improving the overall health of people.
Tenet Healthcare (THC) Rides on Strong Patient Volumes, Buyouts
by Zacks Equity Research
Tenet Healthcare (THC) gains from expanding patient admissions, diversified treatment network, acquisitions and robust cash-generating abilities.
Here's Why Hold Strategy is Apt for Teladoc (TDOC) Stock Now
by Zacks Equity Research
Teladoc's (TDOC) BetterHelp business is expected to gain from new member growth and stable customer acquisition costs.
The Joint (JYNT) Forays Into West Virginia Chiropractic Market
by Zacks Equity Research
The Joint's (JYNT) new facility is positioned near the West Virginia University campus, at a high-traffic shopping center.
Elevance Health (ELV) Hits Pause on $2.5B BCBSLA Acquisition
by Zacks Equity Research
Elevance Health (ELV) and BCBS Louisiana have opted to withdraw the acquisition application from the Louisiana Department of Insurance.
Tenet Healthcare (THC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Tenet Healthcare (THC) closed the most recent trading day at $67.73, moving +0.59% from the previous trading session.
Why Investors Are Retaining Pediatrix Medical (MD) Stock Now
by Zacks Equity Research
Pediatrix Medical's (MD) rising net patient service revenues will likely benefit its top line.
Zacks Industry Outlook Highlights HCA Healthcare, Universal Health Services, Tenet Healthcare, Acadia Healthcare and Community Health Systems
by Zacks Equity Research
HCA Healthcare, Universal Health Services, Tenet Healthcare, Acadia Healthcare and Community Health Systems are part of the Zacks Industry Outlook article.
Tenet Healthcare (THC) & Oracle Unite to Improve Efficiency
by Zacks Equity Research
Tenet Healthcare (THC) collaborates with Oracle Cloud HCM to improve and automate human resources and payroll processes.
5 Hospital Stocks to Watch Amid Improving Industry Trends
by Kaibalya Pravo Dey
Cost optimization efforts and rising patient volumes for the Zacks Medical-Hospital industry players are major positives. HCA, UHS, THC, ACHC and CYH are poised to gain from improving occupancy rates.
Here's Why Investors are Buying HCA Healthcare (HCA) Stock Now
by Zacks Equity Research
With seniors resuming delayed elective procedures, demand for services provided by HCA Healthcare (HCA) is likely to rise.
Should Value Investors Buy Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tenet Healthcare (THC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tenet Healthcare (THC) closed at $70.98, marking a +0.45% move from the previous day.
Wall Street Analysts Think Tenet (THC) Could Surge 25.19%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Tenet (THC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tenet Healthcare (THC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Tenet Healthcare (THC) closed at $77.24, marking a +0.78% move from the previous day.
Tenet Healthcare (THC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Tenet Healthcare (THC) closed at $77.56 in the latest trading session, marking a -1.08% move from the prior day.
Why Investors Are Snapping Up Tenet Healthcare (THC) Stock Now
by Zacks Equity Research
Tenet Healthcare (THC) patient volumes are likely to remain high as seniors resume elective procedures, which were delayed due to pandemic-related constraints.
Tenet Healthcare (THC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Tenet Healthcare (THC) closed the most recent trading day at $74.23, moving +0.49% from the previous trading session.
Are Investors Undervaluing Tenet Healthcare (THC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Universal Health (UHS) Gains From Solid Segmental Performance
by Zacks Equity Research
Universal Health (UHS) gains from the uptrend in revenue growth, which in turn, is derived from expanding patient volumes. A credible financial position drives its expansion endeavors.
Encompass Health's (EHC) Q2 Earnings Beat, '23 EPS View Raised
by Zacks Equity Research
Encompass Health's (EHC) Q2 results reflect a growing patient base and improved net patient revenue per discharge. Management anticipates 2023 adjusted EPS within $3.31-$3.53, up from the earlier view of $2.94-$3.23.
Tenet Healthcare (THC) Q2 Earnings Beat on Solid Hospital Unit
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results gain on improved adjusted admissions and higher pricing yield. Management expects adjusted EPS of $5.18-$6.03 for this year.
Compared to Estimates, Tenet (THC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Tenet (THC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tenet Healthcare (THC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 14.29% and 3.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 10.84% and 3.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?